These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, Goldman Sachs reiterated a Neutral rating with a price target of $26.00 for Arrowhead Pharma (NASDAQ:ARWR), which currently trades at $15.21, near its 52-week low. According to InvestingPro data, analyst targets range from $21 to $80, reflecting diverse opinions on the company’s potential. The firm’s analyst highlighted the initial topline data from a Phase 1/2 study of ARO-C3, a treatment for patients with IgA Nephropathy. The study showed significant reductions in C3 and alternative pathway complement activity, as well as a 41% reduction in urine protein creatinine ratio (UPCR) by week 24.
The data indicated that ARO-C3 led to a mean sustained reduction in C3 of over 87% from baseline through week 24. It also showed mean sustained reductions in AH50/Wieslab AP of at least 76%/89%, respectively, through the same period. These results suggest the potential of ARO-C3 in treating IgA Nephropathy, although Goldman Sachs emphasized the necessity for longer-term data to assess whether reductions in UPCR will deepen or plateau. While the company maintains a strong liquidity position with a current ratio of 6.09, InvestingPro analysis indicates it’s quickly burning through cash, with a net loss of $639.71 million in the last twelve months. Further data is anticipated to be presented at a medical meeting in 2025.
Goldman Sachs also noted that Arrowhead Pharma is focusing on its cardiometabolic franchise in the near term. The company is preparing for the launch of plozasiran for familial chylomicronemia syndrome (FCS) with a PDUFA date set for November 18, 2026. Additionally, Arrowhead is close to completing enrollment in multiple severe hypertriglyceridemia (sHTG) trials, with data expected in 2026.
Moreover, the firm is progressing in its obesity vertical, anticipating initial monotherapy data from the ARO-INHBE Part 1 study by the end of 2025 and commencing dosing for Phase 1 of ARO-ALK7 in mid-2025. The analyst’s commentary suggests cautious optimism about the therapeutic potential of ARO-C3, while also pointing to the broader strategic initiatives Arrowhead is undertaking in its product pipeline. With analysts projecting 36.67% revenue growth for FY2025, investors seeking deeper insights can access comprehensive analysis and 10+ additional ProTips through InvestingPro’s detailed research reports, which provide expert analysis on this and 1,400+ other US stocks.
In other recent news, Arrowhead Pharmaceuticals has announced promising results from its Phase 1/2 study of the investigational drug ARO-C3 for IgA nephropathy, showing significant reductions in disease markers and proteinuria. The treatment was well-tolerated, with no serious adverse events reported. Additionally, Arrowhead is advancing its RNA interference-based obesity treatments, ARO-INHBE and ARO-ALK7, into clinical trials following impressive preclinical results. The company has also launched a new website and white paper to support individuals with Familial Chylomicronemia Syndrome as part of its We’ll Get There Soon campaign. RBC Capital Markets maintained an Outperform rating on Arrowhead, highlighting the company’s recent transaction with Sarepta Therapeutics (NASDAQ:SRPT), which provides financial stability and a focus on cardiometabolic programs. Chardan Capital Markets has reaffirmed a Buy rating with a $60 price target, citing ongoing clinical trials for plozasiran, aimed at treating severe hypertriglyceridemia. These developments reflect Arrowhead’s commitment to advancing its pipeline and addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.